BTIG Maintains Buy on AtriCure, Raises Price Target to $63

BTIG analyst Ryan Zimmerman has maintained a Buy rating on AtriCure (NASDAQ: ATRC) and increased the price target from $55 to $63. This adjustment reflects a positive outlook for the company's performance in the market.